TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03593252
Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative used for bowel preparation
Study: NCT00002309
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05527457
Drug: BAY2586116
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg BAY2586116 nasal spray application
Study: NCT05527457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) nasal spray application
Study: NCT05707325
Drug: engineered red blood cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: engineered red blood cell
Study: NCT06484790
Drug: NW-301V
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-T T cell targeting KRAS G12V mutation
Study: NCT06484790
Drug: NW-301D
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-T T cell targeting KRAS G12D mutation
Study: NCT05571787
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
Study: NCT01523379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl i.v. two times a day, two days in an row
Study: NCT05013463
Drug: Indapamide Pill
Normalized name: indapamide Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Indapamide, 2.5 mg OD
Study: NCT03824847
Drug: Clarithromycin 250 MG
Normalized name: clarithromycin 250 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 1 tablet (250mg) twice daily for three days
Study: NCT03824847
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
Study: NCT04813471
Drug: Endothelial Protocol
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial Protocol
Study: NCT06377826
Drug: medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be just on medication and no exercise will be given to this group
Study: NCT05361330
Drug: Shuganjieyu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
Study: NCT05361330
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
Study: NCT04746963
Drug: AXT107 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
Study: NCT04746963
Drug: AXT107 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
Study: NCT04746963
Drug: AXT107 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
Study: NCT06509568
Drug: Neoadjuvant chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
Study: NCT04938635
Drug: VIT-2763 60 mg QD
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
Study: NCT04938635
Drug: VIT-2763 60 mg BID
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
Study: NCT04938635
Drug: VIT-2763 120 mg BID
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
Study: NCT04938635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
Study: NCT05363280
Drug: AL8326 middle dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken AL3826 at middle dose orally
Study: NCT00000640
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06324825
Drug: Fuzhegn Nizeng Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
Study: NCT06450405
Drug: Testosterone Cypionate 50 MG/ML Injectable Solution
Normalized name: testosterone cypionate 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
Study: NCT04859517
Drug: ADG20
Normalized name: Adintrevimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ADG20
Study: NCT06520163
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 6: 6mg
Study: NCT06297668
Drug: Treatment B: BGF MDI HFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
Study: NCT06297668
Drug: Treatment C: BGF MDI HFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
Study: NCT05505747
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral placebo will consist of corn starch and gelatin capsules
Study: NCT05997641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually matching 0 mg DF-003 capsules.
Study: NCT04697485
Drug: Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg
Study: NCT06210984
Drug: Low caffeine dose
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg dose of caffeine in pill form
Study: NCT06210984
Drug: Moderate caffeine dose
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/kg dose of caffeine in pill form
Study: NCT06210984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg dose of maltodextrin in pill form
Study: NCT00299208
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04353180
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
Normalized name: isotretinoin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT04353180
Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT04353180
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT06447740
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
Study: NCT05170243
Drug: 9MW1911 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenously on day 1
Study: NCT05170243
Drug: 9MW1911 Injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo intravenously on day 1
Study: NCT04607200
Drug: AGEN2034
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Monoclonal Antibody
Study: NCT04607200
Drug: AGEN1884
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CTLA-4 Monoclonal Antibody
Study: NCT05389722
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06654960
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection single dose.
Study: NCT06539013
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil infusion
Study: NCT06539013
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of Fentanylfor analgesia
Study: NCT06394973
Drug: T4090 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study: NCT06187376
Drug: Chinese Herbal Medicine (CHM) supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dropper of tincture by mouth for 12 weeks.
Study: NCT06187376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tincture.
Study: NCT04260217
Drug: APG2575 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG2575 400 mg
Study: NCT04260217
Drug: APG2575 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG2575 600 mg
Study: NCT04260217
Drug: APG2575 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG2575 800 mg
Study: NCT06654596
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
Study: NCT06096597
Drug: Clarix Flo
Normalized name: Aller-Flo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
Study: NCT06096597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.9% preservative-free sodium chloride
Study: NCT05667714
Drug: SA58 Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Study: NCT05667714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided by Sinovac Life Sciences Co. , Ltd.
Study: NCT05913414
Drug: Polysaccharide Iron Complex Pill
Normalized name: polysaccharide iron complex Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
Study: NCT03948022
Drug: Crinone 8% Vaginal Gel
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg daily vaginal gels
Study: NCT05748990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Study: NCT06198673
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
Study: NCT05800249
Drug: PE0116
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
Study: NCT05819918
Drug: Best available therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
Study: NCT05875506
Drug: doxycycline hyclate saturated chitosan dressing
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
Study: NCT04730648
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
Study: NCT05268926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05972460
Drug: IMM2510
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
Study: NCT05279846
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically for 48 weeks
Study: NCT06191094
Drug: sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
Study: NCT04417894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for SC injection administration
Study: NCT06560294
Drug: Micronized purified flavonoid fraction (Daflon ®)
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
Study: NCT04630834
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
Study: NCT04630834
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
Study: NCT04630834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
Study: NCT06554717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo injection given subcutaneously daily
Study: NCT04830462
Drug: Rifampicin 300 Mg Oral Capsule
Normalized name: Rifampicin 300 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg orally once daily for 4 months
Study: NCT06146374
Drug: SLV213
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
Study: NCT06784349
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as per the protocol
Study: NCT06409377
Drug: Precedex 200 MCG in 2 ML Injection
Normalized name: Precedex 200 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
Study: NCT04741477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo product (without cannabinoids) will be topically applied
Study: NCT05495893
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
Study: NCT05236998
Drug: SID1903 (FDC)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of SID1903 (FDC) after an overnight fast
Study: NCT05105490
Drug: PerQdisc
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [BEAUTY SHIELD BROAD SPECTRUM SUNSCREEN (Napoleon Perdis)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational trial to collect post-market safety and efficacy information in a limited number of human patients
Study: NCT05549115
Drug: clarithromycin-sensitive(first-line)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
Study: NCT05549115
Drug: clarithromycin-resistant(first-line)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
Study: NCT05549115
Drug: empirical therapy group first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
Study: NCT06374901
Drug: SOX/XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment with SOX/XELOX
Study: NCT04754451
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attach two lidocaine patches for 12 hours, one above and below the incision site.
Study: NCT05664919
Drug: SA58 Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Study: NCT06244758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is administered orally.
Study: NCT05868200
Drug: Capitano zenzero toothpaste
Normalized name: Lespedeza capitata flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Study: NCT05868200
Drug: Colgate total toothpaste
Normalized name: Colgate Total Toothpaste Whitening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Study: NCT04223310
Drug: Virtual AAD TEST group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design.
Study: NCT04223310
Drug: Empirical AAD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design.
Study: NCT06410612
Drug: PAI
Normalized name: PAI-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: this is the no block portion of the study
Study: NCT04732182
Drug: Standard of Care medication for early Alzheimer's Disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
Study: NCT00005112
Drug: Human recombinant growth hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06555601
Drug: UCB3101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive UCB3101 as prespecified in each cohort.
Study: NCT06555601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
Study: NCT05452785
Drug: DFD-29 (Minocycline) Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.